What is Relmada Therapeutics, Inc.'s (RLMD) StockRank?

MoatMap's StockRank for Relmada Therapeutics, Inc. (RLMD) is 51/100, with a Hold signal. This is a composite score combining Quality (40), Value (42), and Momentum (63) factor ranks across MoatMap's 20,000+ stock universe.

Does Relmada Therapeutics, Inc. have an economic moat?

Relmada Therapeutics, Inc. (RLMD) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Relmada Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Relmada Therapeutics, Inc. (RLMD) is Hold, based on a StockRank of 51/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Relmada Therapeutics, Inc. in?

Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

RLMD

HOLD

Relmada Therapeutics, Inc. · Healthcare · United States · $544M · Avg Vol: $12M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-25.6%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on major depressive disorder (MDD) and neuropathic pain. The company's lead investigational compound, REL-1017, is a novel NMDA receptor modulator with the potential to offer a new approach for treating depression. Relmada operates as a niche biotech player with its pipeline concentrated on high-unmet-need CNS conditions.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-1.52	-0.94	-0.76	-1.45	—	-1.04
Shares	105.0M	105.0M	105.0M	73.3M	-30.2%	—
Debt	—	—	—	—	—	—
Equity	140.4M	85.4M	35.5M	86.5M	-14.9%	—
Op CF	-103.8M	-51.7M	-51.8M	-45.8M	—	-12.1M
Inv CF	19.7M	50.5M	51.6M	-48.1M	—	—
Fin CF	45.0M	-98.5K	-40.3K	93.6M	—	—

Loading 1Y...

PRICE (1Y)-20.6%

SMA 50SMA 200

$5.18

RSI (14)

27.8

52W High

$8.00

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-67.5%10.6

ROE

-25.6%29.0

GP/Assets

—N/A

Op. Margin

0.0%41.3

FCF/Assets

-8.2%31.0

Piotroski

458.0

Int. Cover

—N/A

D/E Ratio

0.00x93.5

Current Ratio

80.21x99.5

Value

P/E (TTM)

—N/A

EV/EBITDA

4.3x94.6

P/FCF

—N/A

P/B

6.1x22.1

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

65%46.0

RS 6M

23%88.0

SMA 50/200

1.26x92.5

EPS Rev 4W

0.0%62.5

EPS Rev 12W

0.0%56.7

EPS Improve

+61%60.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$544M

P/E (Forward)

-12.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RLMD are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
RLMD	Relmada Therapeutics, Inc.(you)	$544M	51	HOLD
FTH	Faeth Therapeutics, Inc.	$729M	47	HOLD
FENC	Fennec Pharmaceuticals Inc.	$347M	53	HOLD
MNPR	Monopar Therapeutics Inc.	$736M	44	HOLD
TBPH	Theravance Biopharma, Inc.	$874M	54	HOLD
CTNM	Contineum Therapeutics, Inc.	$526M	37	HOLD
ABEO	Abeona Therapeutics Inc.	$345M	58	HOLD
TECX	Tectonic Therapeutic, Inc.	$573M	36	HOLD
CLYM	Climb Bio, Inc.	$735M	40	HOLD
IKT	Inhibikase Therapeutics, Inc.	$366M	41	HOLD

Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%

Relmada Therapeutics, Inc. (RLMD) — Stock Score Summary

Relmada Therapeutics, Inc. (RLMD) has a MoatMap StockRank of 51/100 based on Quality (40/100), Value (42/100), and Momentum (63/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$5.18
Market Cap	$544M
P/E (Forward)	-12.20
Price/Book	6.07
Return on Equity	-25.6%
Return on Invested Capital	-67.5%
Debt/Equity	0.00x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-8M

Relmada Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Relmada Therapeutics, Inc.’s (RLMD) StockRank?: MoatMap’s StockRank for Relmada Therapeutics, Inc. (RLMD) is 51/100, with a Hold signal. It is a composite of Quality (40), Value (42), and Momentum (63) factor ranks across MoatMap’s 20,000+ stock universe.
Does Relmada Therapeutics, Inc. have an economic moat?: Relmada Therapeutics, Inc. (RLMD) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Relmada Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Relmada Therapeutics, Inc. (RLMD) is Hold, based on a StockRank of 51/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Relmada Therapeutics, Inc. in?: Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).